Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Margolis

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
AIDS and Behavior|May 16, 2020
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 TrialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
Blood|February 10, 2017
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional studyParinda A Mehta, Stella M Davies, Thomas Leemhuis, et al.
Pathogens & Immunity|March 20, 2024
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?Justin Harper, Michael R Betts, Mathias Lichterfeld, et al.
Journal of Clinical Immunology|November 10, 2011
Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011)James W Verbsky, Mei W Baker, William J Grossman, et al.
AIDS and Behavior|February 14, 2020
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077Elizabeth E Tolley, Sahar Z Zangeneh, Gordon Chau, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Culture, Health & Sexuality|May 22, 2020
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and SpainAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
AIDS and Behavior|May 25, 2020
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 WeeksMiranda Murray, Antonio Antela, Anthony Mills, et al.
The Journal of Infectious Diseases|August 31, 2023
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19Mark J Giganti, Kara W Chew, Joseph J Eron, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
AIDS and Behavior|May 16, 2020
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 TrialsAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
Blood|February 10, 2017
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional studyParinda A Mehta, Stella M Davies, Thomas Leemhuis, et al.
Pathogens & Immunity|March 20, 2024
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?Justin Harper, Michael R Betts, Mathias Lichterfeld, et al.
Journal of Clinical Immunology|November 10, 2011
Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011)James W Verbsky, Mei W Baker, William J Grossman, et al.
AIDS and Behavior|February 14, 2020
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077Elizabeth E Tolley, Sahar Z Zangeneh, Gordon Chau, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Culture, Health & Sexuality|May 22, 2020
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and SpainAndrea Mantsios, Miranda Murray, Tahilin S Karver, et al.
AIDS and Behavior|May 25, 2020
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 WeeksMiranda Murray, Antonio Antela, Anthony Mills, et al.
The Journal of Infectious Diseases|August 31, 2023
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19Mark J Giganti, Kara W Chew, Joseph J Eron, et al.
Pageof 12